Olaratumab Approved for Soft-Tissue Sarcoma.

The FDA has granted accelerated approval to the monoclonal antibody olaratumab, combined with doxorubicin, as first-line therapy for patients with inoperable soft-tissue sarcoma. In a randomized phase II trial, the median overall survival was 26.5 months for patients who received this combination, versus 14.7 months for those who received only doxorubicin. ©2016 American Association for Cancer Research.

RCT Entities:   Population Interventions Outcomes